English

INTERIM REPORT JANUARY-MARCH 2014 CHRONTECH PHARMA

Report this content

  • Research and development costs amounted to SEK 0.4 (0.0) m
  • Loss after tax was SEK -1.4 (-1.5) m
  • Earnings per share were SEK -0.01 (-0.01)
  • The company had no net sales for the period
  • ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV

EVENTS AFTER THE END OF THE REPORTING PERIOD

  • Another 8,356,123 convertibles have been converted into shares during the period. 78,501,660 convertibles of the 100,862,727 convertibles subscribed for in September 2013 have now been converted into shares.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

Documents & Links